Title
Effect of conjugated estrogens with and without medrogestone: A prospective study
Author
Gaubius Instituut TNO
van der Mooren, M.J.
Gevers Leuven, J.A.
Rolland, R.
Publication year
1994
Abstract
Objective: To study the possible changes in serum lipids and lipoproteins during hormone replacement therapy with special emphasis on the possible effects brought about by the progestogen. Design: Open-label randomized prospective comparative study. Setting: Gynecological outpatient department of a university hospital. Patients: Thirty-three healthy hysterectomized postmenopausal women. Interventions: Continuous oral supplementation with conjugated estrogens, 0.625 mg daily, was administered either alone (group I; N = 18) or in combination with cyclic medrogestone, 5 mg daily during the last 12 days of each 28 days treatment cycle (group II; N = 15). Main outcome measure: Changes in serum lipids, lipoproteins and apolipoproteins after three, six and 13 treatment cycles. Results: After 1 year of treatment significant increases were observed in mean high-density lipoprotein (HDL) cholesterol, its subfractions, and apolipoprotein A-I in group I and II: HDL cholesterol: +25.2% and +12.1%, respectively; HDL2 cholesterol: +47.4% and +23.5%, respectively; HDL3 cholesterol: +18.1% and +11.2%, respectively; apolipoprotein A-I: +23.0 and +14.8%, respectively. Comparing the two study groups no significant differences were found in lipid changes during the study period, except for HDL2 cholesterol. Conclusion: Supplementation with conjugated estrogens, with and without medrogestone, and given for a longer period, demonstrated a beneficial influence on serum lipoproteins with almost no differences between the two treatment regimens. Chemicals/CAS: Apolipoproteins; Cholesterol, 57-88-5; Cholesterol, HDL; Cholesterol, LDL; Estrogens, Conjugated (USP); Lipids; Lipoproteins; Medrogestone, 977-79-7; Triglycerides
Subject
Administration, Oral
Apolipoproteins
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Climacteric
Dose-Response Relationship, Drug
Drug Administration Schedule
Estrogen Replacement Therapy
Estrogens, Conjugated (USP)
Female
Humans
Hysterectomy
Lipids
Lipoproteins
Medrogestone
Middle Aged
Prospective Studies
Triglycerides
To reference this document use:
http://resolver.tudelft.nl/uuid:bcd60daa-3497-4d00-8f79-704e11a8afc5
DOI
https://doi.org/10.1016/0378-5122(94)90039-6
TNO identifier
280585
ISSN
0378-5122
Source
Maturitas, 19 (19), 33-42
Document type
article